249 related articles for article (PubMed ID: 30291220)
1. AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer.
Axelrod HD; Valkenburg KC; Amend SR; Hicks JL; Parsana P; Torga G; DeMarzo AM; Pienta KJ
Mol Cancer Res; 2019 Feb; 17(2):356-369. PubMed ID: 30291220
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer.
Mishra A; Wang J; Shiozawa Y; McGee S; Kim J; Jung Y; Joseph J; Berry JE; Havens A; Pienta KJ; Taichman RS
Mol Cancer Res; 2012 Jun; 10(6):703-12. PubMed ID: 22516347
[TBL] [Abstract][Full Text] [Related]
3. GAS6 receptor status is associated with dormancy and bone metastatic tumor formation.
Taichman RS; Patel LR; Bedenis R; Wang J; Weidner S; Schumann T; Yumoto K; Berry JE; Shiozawa Y; Pienta KJ
PLoS One; 2013; 8(4):e61873. PubMed ID: 23637920
[TBL] [Abstract][Full Text] [Related]
4. Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy.
Cackowski FC; Eber MR; Rhee J; Decker AM; Yumoto K; Berry JE; Lee E; Shiozawa Y; Jung Y; Aguirre-Ghiso JA; Taichman RS
J Cell Biochem; 2017 Apr; 118(4):891-902. PubMed ID: 27753136
[TBL] [Abstract][Full Text] [Related]
5. Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow.
Yumoto K; Eber MR; Wang J; Cackowski FC; Decker AM; Lee E; Nobre AR; Aguirre-Ghiso JA; Jung Y; Taichman RS
Sci Rep; 2016 Nov; 6():36520. PubMed ID: 27819283
[TBL] [Abstract][Full Text] [Related]
6. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
[TBL] [Abstract][Full Text] [Related]
7. Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival.
van Ginkel PR; Gee RL; Shearer RL; Subramanian L; Walker TM; Albert DM; Meisner LF; Varnum BC; Polans AS
Cancer Res; 2004 Jan; 64(1):128-34. PubMed ID: 14729616
[TBL] [Abstract][Full Text] [Related]
8. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target.
Paccez JD; Vasques GJ; Correa RG; Vasconcellos JF; Duncan K; Gu X; Bhasin M; Libermann TA; Zerbini LF
Oncogene; 2013 Feb; 32(6):689-98. PubMed ID: 22410775
[TBL] [Abstract][Full Text] [Related]
9. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor.
Sainaghi PP; Castello L; Bergamasco L; Galletti M; Bellosta P; Avanzi GC
J Cell Physiol; 2005 Jul; 204(1):36-44. PubMed ID: 15605394
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the Axl pathway impairs breast and prostate cancer metastasis to the bones and bone remodeling.
Tanaka M; Dykes SS; Siemann DW
Clin Exp Metastasis; 2021 Jun; 38(3):321-335. PubMed ID: 33791875
[TBL] [Abstract][Full Text] [Related]
11. Tumor removal limits prostate cancer cell dissemination in bone and osteoblasts induce cancer cell dormancy through focal adhesion kinase.
Liu R; Su S; Xing J; Liu K; Zhao Y; Stangis M; Jacho DP; Yildirim-Ayan ED; Gatto-Weis CM; Chen B; Li X
J Exp Clin Cancer Res; 2023 Oct; 42(1):264. PubMed ID: 37821954
[TBL] [Abstract][Full Text] [Related]
12. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
[TBL] [Abstract][Full Text] [Related]
13. Imaging Axl expression in pancreatic and prostate cancer xenografts.
Nimmagadda S; Pullambhatla M; Lisok A; Hu C; Maitra A; Pomper MG
Biochem Biophys Res Commun; 2014 Jan; 443(2):635-40. PubMed ID: 24333418
[TBL] [Abstract][Full Text] [Related]
14. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
Choi YJ; Kim JH; Rho JK; Kim JS; Choi CM; Kim WS; Son J; Lee JC
Oncol Rep; 2017 Apr; 37(4):2201-2208. PubMed ID: 28260071
[TBL] [Abstract][Full Text] [Related]
15. Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII-p38MAPK-pS249/T252RB Pathway.
Yu-Lee LY; Yu G; Lee YC; Lin SC; Pan J; Pan T; Yu KJ; Liu B; Creighton CJ; Rodriguez-Canales J; Villalobos PA; Wistuba II; de Nadal E; Posas F; Gallick GE; Lin SH
Cancer Res; 2018 Jun; 78(11):2911-2924. PubMed ID: 29514796
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
18. [Expression of AXL enhances docetaxel-resistance of prostate cancer cells].
Lin JZ; Zhu JG; Wu HF; Li JM; DE W; Wang ZJ
Zhonghua Nan Ke Xue; 2017 Apr; 23(4):302-308. PubMed ID: 29714413
[TBL] [Abstract][Full Text] [Related]
19. AXL is an essential factor and therapeutic target for metastatic ovarian cancer.
Rankin EB; Fuh KC; Taylor TE; Krieg AJ; Musser M; Yuan J; Wei K; Kuo CJ; Longacre TA; Giaccia AJ
Cancer Res; 2010 Oct; 70(19):7570-9. PubMed ID: 20858715
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma.
Chen L; Kong G; Zhang C; Dong H; Yang C; Song G; Guo C; Wang L; Yu H
Oncotarget; 2016 Apr; 7(15):20041-53. PubMed ID: 26942465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
